599 related articles for article (PubMed ID: 29334901)
1. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
2. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
3. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
4. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
Dominiak-Felden G; Gobbo C; Simondon F
PLoS One; 2015; 10(7):e0132404. PubMed ID: 26147096
[TBL] [Abstract][Full Text] [Related]
6. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection.
Saccucci M; Franco EL; Ding L; Bernstein DI; Brown D; Kahn JA
Sex Transm Dis; 2018 Apr; 45(4):260-265. PubMed ID: 29465705
[TBL] [Abstract][Full Text] [Related]
7. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
8. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
[TBL] [Abstract][Full Text] [Related]
10. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
[TBL] [Abstract][Full Text] [Related]
11. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
[TBL] [Abstract][Full Text] [Related]
12. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
Ährlund-Richter A; Cheng L; Hu YOO; Svensson M; Pennhag AAL; Ursu RG; Haeggblom L; Grün N; Ramqvist T; Engstrand L; Dalianis T; Du J
Front Cell Infect Microbiol; 2019; 9():59. PubMed ID: 30949454
[No Abstract] [Full Text] [Related]
13. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
Guo F; Hirth JM; Berenson AB
Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
[TBL] [Abstract][Full Text] [Related]
15. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
Kumakech E; Berggren V; Wabinga H; Lillsunde-Larsson G; Helenius G; Kaliff M; Karlsson M; Kirimunda S; Musubika C; Andersson S
PLoS One; 2016; 11(8):e0160099. PubMed ID: 27482705
[TBL] [Abstract][Full Text] [Related]
16. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
Kudo R; Yamaguchi M; Sekine M; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
J Infect Dis; 2019 Jan; 219(3):382-390. PubMed ID: 30299519
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
[TBL] [Abstract][Full Text] [Related]
18. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
Cuschieri K; Kavanagh K; Moore C; Bhatia R; Love J; Pollock KG
Br J Cancer; 2016 May; 114(11):1261-4. PubMed ID: 27115467
[TBL] [Abstract][Full Text] [Related]
19. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.
Enerly E; Flingtorp R; Christiansen IK; Campbell S; Hansen M; Myklebust TÅ; Weiderpass E; Nygård M
PLoS One; 2019; 14(10):e0223612. PubMed ID: 31600341
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
